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Combinatorial gene and cell therapy as a means of generating surrogate β-cells has been investigated for 20 
the treatment of type 1 diabetes (T1D) for a number of years with varying success. One of the limitations 21 
of current cell therapies for T1D is the inability to generate sufficient quantities of functional, 22 
transplantable insulin-producing cells. Due to their impressive immunomodulatory properties, in addition 23 
to their ease of expansion and genetic modification ex vivo, mesenchymal stem cells (MSC) are an 24 
attractive alternative source of adult stem cells for regenerative medicine. To overcome the 25 
aforementioned limitation of current therapies, we assessed the utility of ex vivo expanded bone-marrow 26 
derived murine MSCs for their persistence in immune-competent and immune-deficient animal models, 27 
and their ability to differentiate into surrogate β-cells.  28 
CD45-/Ly6+ murine MSCs were isolated from the bone marrow of non-obese diabetic (NOD) mice and 29 
nucleofected to express the bioluminescent protein, Firefly luciferase (Luc2). The persistence of a 30 
subcutaneous (s.c) transplant of Luc2-expressing MSCs was assessed in immune-competent (NOD) (n=4) 31 
and immune-deficient (NOD/Scid) (n=4) animal models of diabetes. Luc2-expressing MSCs persisted for 2 32 
and 12 weeks, respectively, in NOD and NOD/Scid mice. Ex vivo expanded MSCs were transduced with the 33 
HMD lentiviral vector (MOI=10) to express furin-cleavable human insulin (INS-FUR) and murine NeuroD1 34 
and Pdx1. This was followed by the characterization of pancreatic transdifferentiation via reverse 35 
transcriptase polymerase chain reaction (RT-PCR), and static and glucose stimulated insulin secretion 36 
(GSIS). INS-FUR-expressing MSCs were assessed for their ability to reverse diabetes after transplantation 37 
into streptozotocin (STZ)-diabetic NOD/Scid mice (n=5). Transduced MSCs did not undergo pancreatic 38 
transdifferentiation, as determined by RT-PCR analyses, lacked glucose-responsiveness, and upon 39 
transplantation did not reverse diabetes.  40 
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The data suggests that ex vivo expanded MSCs lose their multipotent differentiation potential and may be 41 
more useful as gene therapy targets prior to expansion. 42 
Keywords 43 
Mesenchymal stem cells, Type 1 diabetes, Lentivirus, Bioluminescence imaging, Differentiation, Insulin-44 
producing cells 45 
Introduction 46 
T1D results from the autoimmune destruction of the pancreatic insulin-producing β-cells, which leads to 47 
hyperglycaemia and the lifelong dependence on exogenous insulin therapy1. Currently, the only cures for 48 
T1D are pancreas or islet transplantation, however these interventions are limited by a shortage of donor 49 
organs and the requirement for lifelong immunosuppression2. To overcome the limitations of current 50 
therapies, a promising alternative strategy is the ex vivo generation of surrogate β-cells through the 51 
directed-differentiation of non-pancreatic target cells3-10. 52 
Pancreatic transcription factors play an important role both in islet cell differentiation and specialisation, 53 
and mature β-cell function during embryonic and neonatal development and adult life, respectively11, 12.  54 
Our laboratory, and others, have investigated the direct transfer of β-cell transcription factors and insulin 55 
as mediators of pancreatic transdifferentiation in non-pancreatic cells/tissues with varying success3-5, 13-17. 56 
We have previously shown that the endocrine specifying transcription factor, NeuroD1, which lies 57 
downstream of Pdx1 in the transcription factor hierarchy of pancreatic development, was capable of 58 
inducing pancreatic transdifferentiation of a rat hepatocyte cell line (H4IIE). Transdifferentiation was 59 
characterized by the upregulation of both upper and lower-hierarchy pancreatic transcription factors, 60 
without the development of exocrine differentiation12, 18. In addition, due to the over-expression of the 61 
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furin-cleavable human insulin (INS-FUR) gene (a modified form of human pro-insulin, which permits 62 
cleavage into mature insulin via furin enzymes in non-pancreatic cells), these cells were capable of 63 
synthesizing, storing and secreting mature human insulin in a glucose-responsive manner; and reversed 64 
diabetes upon transplantation in STZ-diabetic NOD/Scid mice18. However, one of the current challenges 65 
of clinical translation of combinatorial gene and cell therapies for T1D is upscaling the production of 66 
functional surrogate β-cells19. 67 
Due to their high plasticity, immunomodulatory properties, fewer ethical concerns, and ease of ex vivo 68 
expansion and gene modification20, 21, MSCs are an attractive alternative target cell for the autologous and 69 
allogeneic treatment of T1D. Several studies have investigated the ex vivo targeting of MSCs for 70 
transdifferentiation into islet progenitor cells (IPCs) via viral-mediated transfer of pancreatic transcription 71 
factors14-17. Previously, the transfer of the “master regulator” of pancreatic differentiation, Pdx1, to MSCs 72 
resulted in their differentiation into glucose-responsive IPCs, which reversed diabetes, for a period of 6-8 73 
weeks (experimental endpoint), upon transplantation into STZ-diabetic NOD/Scid mice14. However, Pdx1 74 
transfer has also been associated with exocrine differentiation, and concomitant tissue damage, which is 75 
undesirable for a T1D cell replacement therapy22. Therefore, in this study, we assessed the pancreatic 76 
differentiation potential of ex vivo expanded murine bone-marrow derived MSCs as a pre-clinical model 77 
to overcome the shortage limitations of current therapies, via the over-expression of murine NueroD1 78 
and INS-FUR using a lentiviral vector. We found that due to a loss of the intrinsic multipotent 79 
differentiation potential of MSCs with increasing culture, transcription factor mediated β-cell 80 
differentiation, via the forced expression of NeuroD1 and INS-FUR, failed to occur. This was confirmed via 81 
the over-expression of murine Pdx1, which is known to induce β-cell differentiation of MSCs at early 82 
passage numbers. The data highlights the limited timeframe for MSCs to function as effective gene 83 
therapy targets, and suggests that MSCs do not represent a suitable alternative source of cells to 84 




Sourcing of animals 87 
NOD and NOD/Scid mice were sourced from the Animal Resources Centre (WA, Australia). All animal work 88 
was approved by the UTS Animal Care and Ethics Committee (ACEC 2011-447A; ACEC 2009-244A), and 89 
complied with the Australian code for the care and use of animals for scientific purposes23. 90 
MSC isolation and cell culture 91 
Bone marrow was flushed from the femurs of female NOD mice (6-8 weeks old), and the cell pellet was 92 
resuspended in standard MSC medium (α-minimal essential media [MEM], 1% v/v 100x 93 
Penicillin/Streptomycin/L-Glutamine (P/S/G) with 20% v/v Fetal Bovine Serum [FBS]) (Gibco®, 94 
Thermofisher), and incubated at 37oC/5% CO2. Plastic-adherent stromal cells were sub-cultured for two 95 
passages (with epiphyses) prior to fluorescence-activated cell sorting (FACS). 96 
Passage 2 plastic-adherent stromal cells (5x105 cells) were resuspended in sorting buffer (1x Hanks 97 
Balanced Salt Solution [HBSS] supplemented with 5% v/v FBS) and stained with 0.2mg/ml rat anti-mouse 98 
CD45 monoclonal antibody (mAb) conjugated to allophycocyanin (APC) (BD Pharmingen™, USA) and 99 
0.2mg/ml rat anti-mouse Ly6 (Sca-1) mAb conjugated to phycoerythrin (PE) (BD Pharmingen™, USA). 100 
Stained stromal cells were sorted by FACS at the Advanced Cytometry Facility (Centenary Institute, 101 
Sydney, Australia) using a BD FACSAria™ II flow cytometer, and analysed using BD FACSDiva™ software 102 
(Version 6.1.3). The stromal cells were sorted into CD45-/Ly6+ (MSCs) and CD45+/Ly6+ (double positive) 103 
cell populations. Sorted cells were resuspended in complete medium and incubated at 37oC/5% CO2. 104 
Following cell attachment, 10ng/ml basic fibroblast growth factor (bFGF) was added to the standard 105 
MSC medium, in which the parental stromal cells and sorted cells were cultured thereafter. 106 
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MSC proliferation and clonogenicity 107 
For proliferation assays, MSCs at early (P3-15), mid (P15-30), and late (P30-60) passage number were 108 
seeded in 24-well plates (2.5x103 cells/well) (Falcon® BD Biosciences, San Jose, USA) in triplicate, and 109 
maintained in standard MSC medium for 15 days, with medium replenished weekly. Cell viability was 110 
assessed by Trypan Blue (0.4% v/v; Gibco®, Thermofisher) exclusion. Total cell and viable cell numbers 111 
were determined, and represented as mean ± standard deviation (SD) for each time point (n=3). 112 
For clonogenicity assays, MSCs at early, mid and late passage number were seeded in 10cm2 tissue culture 113 
treated plates (5x102 cells/plate) (Falcon® BD Biosciences), and maintained in standard MSC medium for 114 
10 days. Colonies were stained with 0.4% v/v methylene blue in methanol, and counted by microscopy. 115 
Data were represented as mean colony count per 5000 cells ± SD (n=3). Standard MSC medium was 116 
replenished weekly.   117 
Morphological analysis 118 
Images of four fields of view at 10x or 20x magnification were acquired at early, mid and late passage 119 
number using a Leica© DM microscope (Leica Microsystems©, Weltzar, Germany), and processed using 120 
the image processing software, Leica Application Suite (V4.4.0) (Leica Microsystems©). Scale bars on 121 
figures are equivalent to 100µm. 122 
Gene expression profiling 123 
Total RNA was extracted using TRIzol® Reagent (Thermofisher®, Waltman, USA) and samples were treated 124 
with DNase I, Amplification Grade (Thermofisher®, USA) before cDNA synthesis using SuperScript® III First-125 
Strand Synthesis SuperMix (Thermofisher®, USA). RT-PCR was subsequently performed using an 126 
Eppendorf® Mastercycler (Eppendorf™, Hamburg, Germany) to determine the relative expression levels of 127 
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selected pancreatic genes using GoTaq PCR Mastermix (Promega®, Madison, USA), and the previously 128 
published oligonucleotide sequences and optimised PCR protocols (Supplementary Table 1)4. PCR 129 
products were imaged after electrophoresis on a 1% w/v agarose gel stained with 10000x GelRed™ 130 
(Biotium®, Fremont, USA) (1:100000) on the InGenius3 (Syngene®, Frederick, USA) UV transilluminator 131 
using the GeneSys image acquisition software (Syngene®). 132 
Differentiation assays 133 
Adipogenesis 134 
Early, mid and late passage number cells were seeded in standard MSC medium in 24-well plates (2.5x104 135 
cells/well) in triplicate and grown to 80-90% confluency. The medium was subsequently replenished with 136 
either adipogenic control or differentiation medium, as previously described24. The cells were stained with 137 
0.2% w/v Oil Red O in methanol (Fronine®, Sydney, Australia), and semi-quantitatively scored as previously 138 
described 24. Values were expressed as count per cm2 and were represented as means ± SDs (n=3).  139 
Osteogenesis 140 
Early, mid and late passage cells were seeded in standard MSC medium in 24-well plates (1.25x104 141 
cells/well) in triplicate and grown to 90-95% confluence. The medium was subsequently replenished with 142 
either osteogenic control or differentiation medium, as previously described24. The cells were stained with 143 
2% w/v Alizarin Red S (pH 4.1) (Fronine®) and semi-quantitatively scored, as previously described24. Values 144 




Early, mid and late passage cells were seeded in 24-well plates (1.25x104 cells/well) and grown to 90% 147 
confluence in standard MSC medium. The medium was subsequently replenished with either control 148 
(MesenCult™-ACF Chondrogenic Differentiation Basal Medium [STEMCELL Technologies®, Vancouver, 149 
Canada] with 2mM L-glutamine) or differentiation (MesenCult™-ACF Chondrogenic Differentiation Basal 150 
Medium, 2mM L-glutamine, MesenCult™-ACF 20X Chondrogenic Differentiation Supplement) medium, 151 
and incubated at 37oC/5% CO2 for 18 days. On day 18, the cells were fixed in 10% v/v neutral buffered 152 
formalin and stained with Alcian blue solution (8x, pH2.5) (Sigma-Aldrich™, Sydney, Australia). 153 
Chondrogenesis was visualised by Alcian blue staining of filamentous glycosaminoglycans. 154 
Construction of mammalian plasmid pVITRO-Luc2 155 
The manipulation of genetic material and generation of genetically modified organisms was approved by 156 
the UTS Biosafety Committee (2001-19-R-GC; 2009-02-R-GC). The luciferase reporter gene Luc2 (Photinus 157 
pyralis), encoded within the vector pGL4.20 (Luc2/Puro) (Promega®, Ipswich, USA) was digested with the 158 
restriction enzymes, EcoRV-HF® and BamHI-HF® (New England Biolabs®, San Diego, USA), and ligated into 159 
the mammalian dual expression plasmid pVITRO2-hygro®-mcs (InvivoGen®, San Diego, USA), to generate 160 
the mammalian bioluminescence plasmid pVITRO2-Luc2 (Supplementary Fig. 1a).  161 
Nucleofection 162 
Early passage MSCs (1x106 cells) were nucleofected with 5µg pVITRO2-Luc2 and 2µg pmax-GFP®, according 163 
to the manufacturer’s instructions (Lonza™, Basel, Switzerland), using the Nucleofector™ 2b device 164 
(Lonza™). Following nucleofection, the cells were returned to culture in standard MSC medium at 37oC/5% 165 
CO2 for one week. Stable clones were then selected using 200µg/ml Hygromycin B (Thermofisher 166 
Scientific®) over a two-week period.  167 
In vitro bioluminescence imaging (BLI) 168 
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In vitro BLI of a linear concentration of mid-passage MSC-Luc2, and the cell line MSC-Luc2/LacZ ID7 169 
(positive control), was performed in 96-well ViewPlate microplates (PerkinElmer®, Waltman, USA). Cells 170 
were attached overnight and imaged on the IVIS Lumina II (PerkinElmer®) following the addition of 171 
150µg/ml D-Luciferin (Gold Biotechnology®, St. Louis, USA). For quantification, a region of interest (ROI) 172 
was manually selected using the Living Image (Version 3.1) software. BLI intensity values were 173 
represented as the mean average radiance ± SD (p/s/cm2/sr). 174 
In vivo MSC persistence  175 
NOD (n=4) and NOD/Scid (n=4) mice (6-10 weeks of age), received a total of six subcutaneous (s.c.) 176 
injections of 1x104 (n=2), 1x105 (n=2) and 1x106 (n=2) mid-passage MSC-Luc2 cells/mouse. Untreated age-177 
matched NOD (n=2) and NOD/Scid (n=2) mice were utilized as negative controls. Mice were anaesthetised 178 
using 2.5% Isoflurane carried in O2 (1.5L/min), transferred to the IVIS Lumina II imaging unit, and 179 
maintained under anaesthesia. BLI images were acquired 5 min after the intraperitoneal (i.p.) injection of 180 
D-luciferin (15mg/mL) at 150mg/kg or 10µL/g. For quantification, ROI were manually selected using the 181 
Living Image (Version 3.1) software. BLI intensity values were presented as the mean average radiance ± 182 
standard errors of means (SEMs) (p/s/cm2/sr). 183 
Construction of lentiviral plasmids 184 
The pHMD and pHMD-INS-FUR lentiviral plasmids 3-5 were modified to express INS-FUR and the human 185 
codon-optimized murine (Mus musculus) Neurod1 and Pdx1 genes. Using GeneArt Gene Synthesis™ 186 
(Thermofisher®, USA), murine Neurod1 cDNA (NM_010894) was synthesized linked to eGFP via a T2A 187 
peptide at the C-terminus. The Neurod1-T2A-eGFP sequence was PCR amplified using the forward and 188 
reverse primers, 5’-GATACTTGGCCATATGACCAAATCATACAGCGA-3’ and 5’-CCATGAGGCCCAGTTAAT-3’, 189 
containing MscI and the PacI restriction sites, respectively. PCR amplified Neurod1-T2A-eGFP was ligated 190 
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into pHMD and pHMD-INS-FUR following digestion with MscI and PacI (New England Biolabs®, Waltman, 191 
USA) to generate pHMD-Neurod1 and pHMD-Neurod1/INS-FUR, respectively.  192 
The pAAV-Pdx1 plasmid (donated by Dr Grant Logan, Children’s Medical Research Institute, Westmead 193 
Children’s Hospital, Sydney, Australia) containing the murine Pdx1 cDNA (NM_008814.3) and the 194 
fluorescent reporter mCherry upstream and downstream of the internal ribosomal entry site (IRES), 195 
respectively, was used to clone murine Pdx1 into the HMD lentiviral plasmid. The Pdx1-IRES-mCherry 196 
sequence was PCR amplified using the forward and reverse primers, 5’-197 
GATACTGGATCCATGAACAGCGAGGAACAG-3’ and 5’-GCGCCGTTAATTAATTACTTGTACAGCTCGTC-3’, 198 
containing BamHI and PacI restriction sites, respectively. PCR amplified Pdx1-IRES-mCherry was ligated 199 
into pHMD following digestion with BamHI-HF® and PacI (New England Biolabs®, USA) to generate pHMD-200 
Pdx1. Schematic representations of the cloned lentiviral plasmids are illustrated in Supplementary Fig. 201 
1b. 202 
Lentiviral vector propagation and titration 203 
Lentiviral plasmids were co-transfected into HEK293T cells using calcium phosphate precipitation as 204 
previously described3-5. Lentiviral particles were harvested at 36, 48, 60 and 72 hrs post-transfection, 205 
filtered through Millex-HV 0.45µM polyvinylidene fluoride syringe filters (EMD Millipore©, Burlington, 206 
USA), and concentrated using Amicon Ultra 100 kDa filters (EMD Millipore©, USA). Concentrated lentiviral 207 
particles were titered using NIH3T3 cells and FACS analysis of eGFP and mCherry expression. Flow 208 
cytometry data was analyzed using BD FACSDiva™ software (Version 8.0.1). 209 
Viral transduction 210 
Mid-passage MSC-Luc2 (1x105 cells/well) were transduced overnight (MOI=10) with HMD, HMD-INS-FUR, 211 
HMD-Neurod1, HMD-Neurod1/INS-FUR, and HMD-Pdx1 in standard MSC medium supplemented with 212 
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8µg/ml Polybrene (Sigma-Aldrich™, Australia). Following transduction, lentiviral particles were removed 213 
and the cells cultured for 72 hrs, after which the cells were sorted into eGFP+ and mCherry+ populations 214 
at the Advanced Cytometry Facility (Centenary Institute, Sydney, Australia) using a BD FACSAria™ II, and 215 
analysed using BD FACSDiva™ software (Version 6.1.3). Fluorescence imaging of positively transduced 216 
MSCs was performed using a Leica© DM microscope (Leica Microsystems©, Australia). 217 
Chronic and acute insulin secretion 218 
For chronic insulin secretion, untransduced and transduced MSCs (1x105 cells/well in triplicate, n=4) were 219 
cultured for 24 hrs in standard MSC medium. For glucose-stimulated insulin secretion, untransduced and 220 
transduced MSCs (1x105 cells/well in triplicate, n=3) were seeded in 6-well plates and sequentially 221 
stimulated with 20mM D-Glucose (Sigma-Aldrich™, Australia), as previously described25. The human insulin 222 
concentrations in harvested supernatants, from both chronic and acute insulin secretion assays, were 223 
quantified using the ARCHITECT™ i4000SR Immunoassay Analyser (Abbott Diagnostics®, Macquarie Park, 224 
Australia). Data were represented as mean insulin concentration (pmol/ml/1x105 cells) ± SD. 225 
Induction of diabetes in NOD/Scid mice 226 
NOD/Scid mice received 170mg/kg of STZ in 0.1M sodium citrate buffer (pH 4.0) via i.p. injection. All 227 
animals, including non-diabetic controls, had their body weights and blood glucose concentrations 228 
measured daily using an Accu-Chek® Performa glucometer (Accu-Chek®, Roche, Castle Hill, Australia). 229 
Animals that did not develop hyperglycaemia (blood glucose concentration >8mmol/L) within 1-week post 230 
STZ-injection received a second low dose (40mg/kg) STZ-injection. Animals that displayed hyperglycaemia 231 
for four consecutive days were considered diabetic and were used for in vivo experiments.  232 
Transplantation of MSC in STZ-NOD/Scid mice 233 
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Two groups of STZ-diabetic NOD/Scid mice received s.c. injections of 1x107 (n=6) and 5x107 (n=6) late 234 
passage INS-FUR-expressing MSCs, respectively. Non-diabetic (n=6) and untreated diabetic (n=6) animals 235 
were assessed alongside treated animals. Body weights and blood glucose concentrations were measured 236 
daily. Animals that displayed hypoglycaemia (blood glucose concentration <3mmol/L) or body weight loss 237 
(>10%) for two consecutive days were euthanized by CO2 asphyxiation and cervical dislocation.  238 
Intraperitoneal glucose tolerance test (IPGTT) 239 
Normal (n=5) and treated (n=3) mice  were fasted for 6 hrs, transferred to a ZDS Qube Manifold 5 Station 240 
(Advanced Anesthesia Specialists®, Australia) and maintained under stable anaesthesia (2.5L/min 241 
isoflurane and 1.5L/min O2). Mice received an i.p. injection of 2g/kg 50% v/v liquid glucose (0.5g/ml). 242 
Blood glucose was measured at 0, 5, 15, 30, 60, and 90 min post-injection. Following IPGTTs, animals were 243 
euthanized by CO2 asphyxiation and cervical dislocation. 244 
Statistical analysis 245 
All statistical analysis was performed using GraphPad Prism 7® software. Values were presented as means 246 
± SDs or SEMs. One-way or two-way ANOVAs, with the appropriate post-tests, were performed, with p< 247 
0.05 indicating significance. 248 
Results 249 
In vitro characteristics of NOD MSCs  250 
MSCs identified by FACS were characterized by the surface marker profile CD45-/Ly6+, and constituted 251 
~33% of the parental stromal cell population (Fig. 1a). MSCs displayed the characteristic fibroblast-like 252 


















Figure 1: In vitro characteristics of NOD derived MSCs with cell culture expansion (a) FACS analysis and enrichment of NOD derived 
MSCs. Following culture for two passages, NOD bone marrow stromal cells were stained with nil antibody (Unstained), CD45 mAb 
conjugated to fluorochrome APC (CD45-APC), Ly6 MAb conjugated to fluorochrome PE (Ly6-PE) and both mAbs (CD45-APC/Ly6-PE).  
Fluorescence dot plots of CD45-APC (y-axis) and Ly6-PE (x-axis) were used to identify the MSC (CD45-/Ly6+; orange) and double positive 
(CD45+/Ly6+; red) cell subpopulations ready for cell sorting using the BD FACSAria™ II instrument. Representative of three individual 
FACS sorting experiments; (b) Plastic adherence, fibroblast-like morphology and self-renewal without differentiation into other cell 
types. MSCs maintained fibroblast-like morphology as assessed using light microscopy (Leica DM microscope; 10x magnification; scale 
bar = 100µM); (c) Improved cell proliferation with culture expansion. Data are presented as mean viable cells ± SDs (n=3). A two-way 
ANOVA with Tukey’s post tests were performed, *p<0.05; (d) Improved fibroblastic colony formation following Methylene blue 
staining. Data are presented as mean number of colonies ± SEMs (n=3). A one-way ANOVA and Tukey’s post tests were performed, * 
p<0.05; (e) Semi-quantitative analysis of adipogenic differentiation under defined conditions. NOD derived MSCs maintained fat 
formation following Oil Red O staining, albeit at reduced levels, with increasing passage number. Data are presented as mean cell 
count/cm2 ± SEM (n=3).  A two way ANOVA and Tukey’s post tests were performed, * p<0.05; (f) Semi-quantitative analysis of 
osteogenic differentiation under defined conditions. NOD derived MSC maintained bone formation following Alizarin Red staining, 
albeit at lower levels, with increasing passage number. Data are presented as mean cell count/cm2 SEM (n=3).  A two way ANOVA and 
Tukey’s post tests were performed, * p<0.05; (g) Pancreatic transcription factor, hormone and protein expression levels were 
determined by RT-PCR. MSCs did not express any transcription factors, hormones or protein found in the pancreas. Positive control 
mouse pancreas (Lane 1), plastic-adherent MSCs (Lane 2), plastic-adherent hematopoietic cells (Lane 3), adherent bone marrow cells 
(Lane 4), and negative control mouse liver (Lane 5). 
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observed with increasing passage, from ~100µm (early passage) to 50µm (late passage). Although MSCs 269 
underwent a period of early passage replicative crisis during P5-8 (data not shown), MSCs continued to 270 
self-renew up to 60 passages (maximum culture period). An intra-population analysis of MSC 271 
proliferation and clonogenicity showed no significant difference in proliferation (Fig. 1c) and 272 
conservation of clonogenicity potency (Fig. 1d) from early to late passage number.  273 
To demonstrate that NOD MSCs underwent tri-lineage differentiation, as defined by the International 274 
Society Cell and Gene Therapy (ISCT), tri-lineage differentiation assays were performed at early, mid and 275 
late passage number. NOD MSC demonstrated tri-lineage differentiation into adipocytes (Supplementary 276 
Fig. 2), osteocytes (Supplementary Fig. 3), and chondrocytes (Supplementary Fig. 4). Semi-quantitative 277 
analysis of adipogenesis and osteogenesis was assessed by scoring the degree of differentiation, as 278 
previously described24. MSCs displayed reduced adipogenesis (Fig. 1e) and osteogenesis (Fig. 1f) with 279 
increasing passage number.  280 
To confirm that MSCs did not intrinsically express any pancreatic transcription factors or hormones, RT-281 
PCR analyses were performed, and showed a lack of expression of pancreatic transcription factors, 282 
hormones and proteins in all adherent bone marrow cell populations (Fig. 1g). As expected, all genes were 283 
expressed in normal mouse pancreas (positive control), and FoxA2, Scl2a2 and Gck were expressed in 284 
normal mouse liver (negative control). 285 
Syngeneic MSCs are cleared in an immune-competent animal model 286 
Non-invasive BLI is an established and sensitive tool for assessing cell replacement therapy safety and 287 
efficacy in living preclinical small animal models. Furthermore, preclinical BLI results often serve as the 288 
decision point of the suitability of a cell replacement therapy for clinical trial testing in humans.  This study 289 
utilized the Firefly luciferase reporter gene, Luc2, a Luc2 specific light producing substrate D-luciferin and 290 
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an IVIS Lumina II imaging system (Perkin Elmer©). Prior to performing in vitro and in vivo BLI, a clonal 291 
population of MSCs expressing Luc2 (MSC-Luc2) was obtained by selection with Hygromycin B. MSC-Luc2 292 
retained a fibroblast-like morphology similar to that observed for parental MSCs (Fig. 2a), however these 293 
cells exhibited a reduced cell diameter (~100µm nucleofected versus 150µm parental). In vitro analyses 294 
of BLI at multiple time-points over a 3-hour period (Fig. 2b), in combination with linear regression analysis 295 
(Fig. 2c), confirmed that a clonal population of MSC-Luc2 had been selected, and that bioluminescence 296 












Figure 2: NOD derived MSC nucleofection (a) MSCs 
(early passage number) were nucleofected with 0 
and 5µg pVITRO2-Luc2. Parental MSCs and MSC-
Luc2 at an equivalent passage number (P15) showed 
native fibroblast-like morphology and maintained 
plastic adherence and self-renewal properties. 
Images were acquired on a Leica DM light 
microscope at 10x magnification, scale bar = 100µm; 
(b) In vitro functional characterization of luciferase 
activity in MSC-Luc2. Cells were incubated with 1:1 
D-luciferin (300µg/ml) and imaged on the IVIS 
Lumina II, according to the in vitro BLI acquisition 
settings. The image represented is at t= 30min after 
the addition of D-luciferin. Lane 1: D-PBS, Lane 2-10: 
MSC-Luc2 and MSC-Luc2/LacZ (control); (c) Linear 
regression analysis of luminescent signal was 
performed using GraphPad Prism 7®. Data are 
presented as means ± SDs of triplicates.  
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We chose to assess the persistence of MSCs transplanted subcutaneously in immune-competent NOD and 309 
immune-deficient NOD/Scid animal models as this most closely reflects the route of administration of a 310 
cell replacement therapy for individuals with T1D. Thus, MSC-Luc2 were transplanted subcutaneously at 311 
multiple cell concentrations to determine the lowest cell concentration and the length of time for which 312 
bioluminescence could be detected (Fig. 3a). Quantitative analysis of BLI data showed that in both 313 
NOD/Scid and NOD mice, there was an increase in bioluminescence with increasing cell dose (Fig. 3b), 314 
which resulted in a dose-dependent increase in persistence of bioluminescence in both animal models 315 
(Supplementary Table 2a & 2b). Bioluminescence, albeit diminished, could be detected in NOD/Scid mice 316 
for up to 12 weeks, suggesting poor survival of MSCs at the s.c transplant site. By comparison, 317 
bioluminescence persisted for 2 weeks in NOD mice, after which signal could no longer be detected, 318 
suggesting an immune-mediated clearing of the MSC graft. In fact, upon challenge with a follow-up 319 
injection of 1x106 MSCs, clearing of the MSC graft occurred within 1 week post-injection (data not shown). 320 
These kinetics are consistent with the generation of memory T cell populations stimulated after the initial 321 
exposure to MSCs. 322 
Neurod1 and Pdx1 fail to induce β-cell differentiation of ex vivo expanded NOD MSCs  323 
The pancreatic transcription factors, Neurod1 and Pdx1, were over-expressed in MSC-Luc2 to function as 324 
mediators of pancreatic transdifferentiation, whilst the INS-FUR gene was over-expressed to allow for 325 
mature human insulin production. Transduced MSCs were analysed via FACS and sorted into individual 326 
populations, as outlined in Supplementary Table 3a & 3b. The sorted MSCs were returned to culture and 327 
imaged for eGFP and mCherry expression 7 days post-transduction (Fig. 4a & 4b). As can be seen, eGFP 328 
expression in MSCs transduced with Neurod1 and INS-FUR/Neurod1 was lower than in cells transduced 329 














 Transduced MSCs were subsequently cultured for a period of 28 days, at which point morphological 342 
analysis of the differentiation process was performed (Fig. 4c). Transduced MSCs expressing both murine 343 
Neurod1 and Pdx1 alone, or in combination with INS-FUR, retained a fibroblast-like morphology in 344 
comparison to their untransduced counterparts, demonstrating that no change in morphology was 345 
attributable to transgene over-expression. 346 
Gene expression profiling was performed to determine if ectopic expression of Neurod1, Pdx1 and INS-347 
FUR in ex vivo expanded MSCs resulted in pancreatic differentiation. As can be seen in Fig. 4d, exogenous 348 
murine Neurod1 was detected at 28 days post-transduction in MSCs transduced with HMD-Neurod1 and 349 
Figure 3: Persistence of syngeneic MSCs in immune-competent and immune-deficient animal models (a) NOD (n=4) and NOD/Scid (n=4) 
mice (6-10 weeks of age), received a total of six subcutaneous (s.c.) injections of 1x104 (n=2), 1x105 (n=2) and 1x106 (n=2) mid-passage MSC-
Luc2 cells/mouse. Untreated age-matched NOD (n=2) and NOD/Scid (n=2) mice were utilized as negative controls.  BLI images were acquired 
following i.p. administration of D-luciferin (15mg/mL) at 150mg/kg or 10µL/g. Images are representative of a single experimental NOD/Scid 
and NOD animal. (b) Analysis of MSC BLI in NOD and NOD/Scid mice. Regions of interest were established surrounding the areas 
corresponding to the sites of cell transplantation using the Living Image 3.1 (PerkinElmer™) software. Quantitative data was subsequently 
analyzed using GraphPad Prism 7®. Data were presented as mean radiance ± SEM over time (weeks). A two-way ANOVA and Tukey’s post 
tests were performed, * p<0.05. 
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HMD-INS-FUR/Neurod1, and, as expected, expression was not detected in the parental MSCs, MSCs 350 
transduced with HMD and HMD-INS-FUR, and the positive control (mouse pancreas). Interestingly, 351 
exogenous Neurod1 expression resulted in the expression of endogenous Neurod1, suggesting a potential 352 
auto-regulatory function of Neurod1. However, Pdx1, Nkx6.1, Scl2a2, Ins1 and Ins2 were not detected in 353 
parental and transduced MSCs. In Fig. 4e, a similar pattern of gene expression was observed following the 354 
ectopic expression of murine Pdx1, as was observed with ectopic expression of Neurod1, with the 355 
exception that ectopic Pdx1 did not result in endogenous Pdx1 expression. Together, these data confirm 356 
the lack of pancreatic differentiation in ex vivo expanded MSC expressing Neurod1 and Pdx1. 357 
Gene-modified ex vivo expanded NOD MSCs demonstrate abnormal glucose stimulated insulin 358 
secretion 359 
The ability of transduced MSCs to secrete mature insulin in vitro in response to glucose stimulation was 360 
determined. A significant quantity of mature insulin (~4.5pmol/ml/1x105 cells) was detected in the 361 
medium of MSCs expressing INS-FUR alone, and in combination with Pdx1. By comparison, untransduced 362 
MSCs, and MSCs transduced with empty vector or Neurod1 alone, did not secrete mature insulin (Fig. 4f). 363 
There was also a significant difference (p<0.005) in the quantity of insulin secreted between MSC-INS-FUR 364 
(~4.5pmol/ml/1x105 cells) and MSC-INS-FUR/Neurod1 (~0.3pmol/ml/1x105 cells), which directly 365 
correlated with differences in the expression of the fluorescent reporter. Acute glucose stimulation assays 366 
showed that following stimulation with 20mM D-Glucose, glucose-stimulated insulin secretion (GSIS) was 367 
not present (Fig. 4g). The absence of GSIS was expected due to the lack of Slc2a2 expression, as detected 368 





















Figure 4: Analysis of INS-FUR, Neurod1 and Pdx1 transduced MSC (a) Fluorescence imaging of MSCs transduced with empty vector (EV), 
Neurod1 and INS-FUR. Transduced cells were returned to culture after sorting for GFP positivity, and imaged for GFP expression (day 7 
post-transduction) using a Leica DM fluorescence microscope (Leica Microsystems), 10x magnification with bright field and GFP 
fluorescence filter sets; scale bar = 100µm. (b) Fluorescence imaging of MSCs and MSC-INS-FUR transduced with Pdx1. Transduced cells 
were returned to culture post-sorting and imaged for GFP and mCherry expression (Day 7 post transduction) using a Leica DM microscope, 
10x magnification under bright field, GFP and Texas Red fluorescence filter sets; scale bar =100µm. (c) Morphological characterization of 
MSCs post-transduction. Bright field images were acquired at 28 days post-transduction on a Leica DM microscope (Leica Microsystems) 
at 10x magnification under bright field setting; scale bar = 100µm. (d) Gene expression profiling of INS-FUR and Neurod1-expressing MSC. 
Lane 1: Untransduced MSC, Lane 2: MSC-EV, Lane 3: MSC-INS-FUR, Lane 4: MSC-Neurod1, Lane 5: MSC-INS-FUR/Neurod1 and Lane 6: 
Mouse pancreas (positive control). (e) Gene expression profiling of Pdx1-expressing MSCs. Lane 1: MSC-Pdx1, Lane 2: MSC-INS-FUR/Pdx1 
and Lane 3: Mouse pancreas (positive control). (f) Chronic insulin secretion from transduced MSCs. Human insulin was quantified using 
the ARCHITECT™ i4000SR Immunoassay Analyser (Abbott Diagnostics©). Data are represented as means ± SDs (n=4). A one-way ANOVA 
with Sidak’s post tests were performed, * p<0.05. (g) Acute glucose-stimulated insulin secretion from INS-FUR and Neurod1 transduced 
MSCs. Human insulin was quantified using the ARCHITECT™ i4000SR Immunoassay Analyser (Abbott Diagnostics©). Data were presented 
as means ± SDs (n=3). Two-way ANOVAs with Tukey’s post tests were performed, * p<0.05. 
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INS-FUR-expressing MSCs fail to restore normoglycaemia in STZ-diabetic NOD/Scid mice 388 
To determine if INS-FUR-expressing MSCs could restore normoglycaemia in STZ-diabetic NOD/Scid mice, 389 
animals received a s.c. transplant of either 1x107 or 5x107 cells. In animals treated with 5x107 cells, within 390 
24-hrs following transplantation there was a decrease in blood glucose concentrations; and a significant 391 
(p<0.05) decrease was observed at days 8 and 12 post-transplantation (Fig. 5a). In addition, there was a 392 
significant decrease in the blood glucose levels of the animals treated with 5x107 cells, from before to 393 
after transplantation, for a period of ~15 days (pre-transplant vs post-transplant, p<0.05) (Supplementary 394 
Table 4a & 4b). By comparison, blood glucose concentrations in diabetic animals, and animals treated 395 
with 1x107 cells, remained significantly higher (p<0.0001) than the normal controls for the duration of the 396 
experiment. Most importantly, animals treated with either 1x107 or 5x107 cells did not normalize blood 397 
glucose concentration at any time for the duration of the experiment. In addition, there was a significant 398 
difference in the body weights of treated animals in comparison to normal controls both before and after 399 
transplantation, despite random allocation of animals to the different groups (Fig. 5b). However, at no 400 
time-point was there a significant decrease in body weight observed over the time course of the 401 
experiment. 402 
Prior to euthanasia, animals treated with 5x107 cells (n=3) were assessed for glucose tolerance via an 403 
IPGTT. Treated animals displayed an abnormal glucose tolerance in comparison to normal controls (Fig. 404 
5c). The high degree of variation in the glucose tolerance observed for the treatment group was due to 405 
one treated animal beginning the IPGTT at a significantly lower blood glucose concentration than the 406 
other treated animals, a consequence of the cell transplant having successfully reduced blood glucose 407 















Stem cells are characterized by two defining long-term characteristics; (i) the ability for renewal without 421 
differentiation into other cell types when cultured under standard conditions, and (ii) the continued 422 
potential to develop into specialized cell types when cultured under defined experimental conditions.  The 423 
early, mid- and late-passage number NOD derived MSCs utilized in this study fulfilled the ISCT criteria of 424 
plastic adherence, self-renewal and colony formation without differentiation into other cell types under 425 
standard MSC culture conditions; and tri-lineage mesenchymal differentiation into bone, fat and cartilage 426 
under defined cell culture conditions20, 21.   427 
Figure 5: Transplantation of MSC-INS-FUR in STZ-diabetic 
NOD/Scid mice (a) Blood glucose concentrations of treated 
STZ-diabetic NOD/Scid mice. Blood glucose measurements 
were recorded daily post STZ-injection for the duration of the 
experiment (36 days). Data were presented as means ± SEMs 
(n=6 mice per group). Two-way ANOVAs with Sidak’s post tests 
were performed, * p<0.05. (b) Body weights of treated STZ-
NOD/Scid mice. Body weight measurements were recorded 
daily post STZ-injection for the duration of the experiment (36 
days). Data were presented as means ± SEMs (n=6 mice per 
group). Two-way ANOVAs were performed with Sidak’s post-
tests, * p<0.05. (c) IPGTT in treated STZ-diabetic NOD/Scid 
mice. Blood glucose measurements were obtained at 0, 5, 15, 
30, 60 and 90 min post D-glucose injection. Data were 
presented as means ± SEMs (n=5; normal, n=3; treated). Two-




In this study, NOD derived MSCs maintained a fibroblast-like morphology, potent self-renewal and 428 
clonogenicity throughout early, mid and late passage numbers. This finding is in contrast to previous 429 
studies, which suggest that MSCs undergo age-related changes with continued cell passage26-28. The 430 
maintenance of a fibroblast-like morphology can be attributed, in part, to medium supplementation with 431 
bFGF. These results are supported by another study, where bFGF inhibited apoptosis and promoted 432 
proliferation of MSCs through a reduction in cellular oxidative stress29. Although MSC characteristics of 433 
self-renewal and colony forming units (CFU-F) were conserved following cell culture expansion, MSCs 434 
showed some reduction in tri-lineage differentiation with increasing passage, which is in concordance 435 
with other studies30-32. Furthermore, several studies have demonstrated the detrimental effect of aging 436 
on multipotential differentiation, proliferation and senescence31, 33, 34. Collectively, these findings highlight 437 
the importance of ongoing surveillance of stem cell-like properties, amongst other defining 438 
characteristics, when engineering replacement cell therapies. 439 
To clarify whether NOD derived MSCs were immune-evasive, we subcutaneously transplanted syngeneic 440 
MSCs into immune-competent NOD mice, which were detectable by BLI up to 14 days post-441 
transplantation. In a similar study, MSCs that were transduced to co-express luciferase and GFP, and 442 
subsequently transplanted via the kidney artery in BALB/c mice, were detected via BLI up to 14 days post 443 
transplantation35. This demonstrates that the site of cell administration in immune-competent models 444 
does not affect cell survival, and that syngeneic MSCs do not appear to be immune-privileged36. This may 445 
be due to several factors, including the over-expression of the non-mammalian Luc2 transgene and 446 
contaminating FBS, factors that may override the inherent immune privilege characteristics of MSCs. In 447 
fact, previous studies have demonstrated that sustained high levels of luciferase expression induce 448 
luciferase-specific immune responses in immune-competent animal models, thereby limiting the utility of 449 
luciferase as an in vivo reporter in transplantation studies37, 38.  450 
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However, in immune-deficient NOD/Scid mice, syngeneic MSCs were detected for a significantly longer 451 
period (up to 12 weeks post-transplantation), albeit with diminishing persistence. These results are 452 
supported by similar studies, which show loss of transplanted MSCs in immune-deficient animal models39-453 
41. The current study highlights the importance of reporter gene selection, and the limited timeframe in 454 
which MSC therapeutic effects can be evaluated, in both immune-competent and immune-deficient 455 
animal models. Assessment of MSCs in short-term studies has demonstrated their protective benefits42, 456 
whereas long-term studies show little or no protection43, which may be attributable to their lack of 457 
persistence in immune-competent models.  458 
We also assessed the ability to differentiate ex vivo expanded MSCs into surrogate β-cells. Considering 459 
the success of Neurod1 as a mediator of β-cell differentiation in non-pancreatic tissues, we sought to 460 
determine the potential of Neurod1 to induce β-cell differentiation of MSCs. In transduced MSCs, over-461 
expression of Neurod1 and INS-FUR did not result in the cuboidal morphological changes associated with 462 
β-cell differentiation. In addition, gene expression profiling confirmed a lack of β-cell differentiation due 463 
to the absence of expression of endogenous pancreatic transcription factors and insulin. A recent study 464 
by Qing-Song et al, assessed the effect of Pdx1, Neurod1 and MafA over-expression in MSCs and showed 465 
that Neurod1 was a weak inducer of endogenous Pdx1 and Ins2 expression, and that only in combination 466 
with Pdx1 and MafA was there significant induction of β-cell differentiation and insulin expression44. 467 
Surprisingly, in this study, the lack of β-cell differentiation following over-expression of Pdx1 in culture-468 
expanded MSCs indicated that ex vivo expansion results in defects in the pancreatic differentiation 469 
potential of MSCs.  470 
A previous study showed that in vivo transplantation is required for functional β-cell maturation45, 471 
therefore INS-FUR-expressing MSCs were assessed for their ability to reverse diabetes following 472 
transplantation into STZ-diabetic NOD/Scid mice. Upon transplantation of 5x107 INS-FUR-expressing 473 
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MSCs, blood glucose concentrations decreased from 25-30 to 15-20mmol/L. However, at no time point 474 
did blood glucose levels fall within the normal physiological range (5-7mmol/L). This is likely due to the 475 
severe hyperglycaemia induced in these animals, which likely requires higher cell numbers to restore 476 
blood glucose levels to within the normal physiological range. Despite this, there was a significant 477 
decrease in the blood glucose levels of treated vs diabetic animals (p<0.05), that was maintained for ~2 478 
weeks, after which blood glucose concentrations began to increase to pre-transplant values. The 479 
subsequent increase in blood glucose concentrations of treated animals correlated with the results of the 480 
MSC persistence studies in NOD/Scid mice. In addition, IPGTTs of transplanted animals showed that they 481 
exhibited abnormal glucose tolerance, indicating a lack of in vivo GSIS. This finding corroborated the in 482 
vitro characterization studies. 483 
In conclusion, the results of this study highlight several caveats to MSC-based gene therapy for T1D, which 484 
warrant careful consideration prior to the formulation of clinical trials. Considering that over-expression 485 
of Pdx1 in early-passage MSCs results in pancreatic differentiation14, these data show that ex vivo 486 
expansion impairs pancreatic differentiation of NOD derived MSCs through the age-related loss of 487 
multipotency. Therefore, gene modification should be performed as soon as practicable after the isolation 488 
of MSCs46. In addition, given that ex vivo expansion is required to generate sufficient quantities of adult 489 
derived MSCs for therapeutic purposes, and that this process impairs their therapeutic potential, the use 490 
of embryonic stem cells or induced pluripotent stem cells as an unlimited stem cell source may overcome 491 
this limitation47, 48.  492 
Data availability 493 
The datasets used and/or analyzed during the current study are available from the corresponding author 494 
upon request.  495 
25 
 
Conflicts of interest 496 
The authors declare that there are no conflicts of interest that could be perceived as prejudicing the 497 
impartiality of the research reported. 498 
Funding 499 
Research was supported by project grants from the Diabetes Australia Research Trust (DART) and the 500 
Rebecca L. Cooper Medical Research Foundation. An Australian Postgraduate Award and a scholarship 501 
from the Arrow Bone Marrow Transplant Foundation supported DG. RH was supported by a UTS Research 502 
Excellence PhD Scholarship and UTS Top-up Scholarship from the Translational Cancer Research Network 503 
(TCRN). 504 
Author contributions 505 
DG: conception and design, collection and presentation of data, data analysis and interpretation, 506 
manuscript writing; RMW: conception and design, DG and RMW performed MSC isolations, RMW 507 
performed MSC nucleofection, data analysis and interpretation, manuscript writing, and final approval of 508 
manuscript. RH performed chondrogenesis assays. BR, NTN and BOB contributed to the study design, data 509 
analysis and interpretation. AMS: financial support, conception and design, data analysis and 510 
interpretation, manuscript writing and final approval of manuscript. All authors read and approved the 511 






Frank Kao and Steven Allen (Advanced Cytometry Facility, Centenary Institute, Sydney, Australia) for their 516 
assistance with FACS sorting. Fiona Ryan and Lalit Overlunde for animal husbandry and assistance with 517 
animal health monitoring (University of Technology Sydney, Australia). 518 
References 519 
1. Atkinson MA, Maclaren NK. The Pathogenesis of Insulin-Dependent Diabetes Mellitus. The New 520 
England Journal of Medicine 1994; 19(331): 1428-1436.  521 
2. Meloche MR. Transplantation for  treatment of type 1 diabetes. World Journal of 522 
Gastroenterology 2007; (13): 6347-6355.  523 
3. Ren B, O’Brien BA, Swan MA, Koina ME, Nassif N, Wei MQ et al. Long-term correction of diabetes 524 
in rats after lentiviral hepatic insulin gene therapy. Diabetologia 2007; 50(9): 1910-1920.  525 
4. Ren B, O'Brien BA, Byrne MR, Ch'ng E, Gatt PN, Swan MA et al. Long-term reversal of diabetes in 526 
non-obese diabetic mice by liver-directed gene therapy. J Gene Med 2013; 15(1): 28-41.  527 
5. Gerace D, Ren B, Hawthorne WJ, Byrne MR, Phillips PM, O'Brien BA et al. Pancreatic 528 
Transdifferentiation in Porcine Liver Following Lentiviral Delivery of Human Furin–Cleavable 529 
Insulin. Transplantation Proceedings 2013; 45(5): 1869-1874.  530 
6. Xie Q-P, Huang H, Xu B, Dong X, Gao S-L, Zhang B et al. Human bone marrow mesenchymal stem 531 
cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. 532 
Differentiation 2009; 77(5): 483-491.  533 
27 
 
7. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH et al. Generation of functional 534 
human pancreatic beta cells in vitro. Cell 2014; 159(2): 428-439.  535 
8. Oh S-H, Muzzonigro TM, Bae S-H, LaPlante JM, Hatch HM, Petersen BE. Adult bone marrow-536 
derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. 537 
Laboratory Investigation 2004; 84(5): 607-617.  538 
9. Tang DQ, Cao LZ, Burkhardt BR, Xia CQ, Litherland SA, Atkinson MA et al. In vivo and in vitro 539 
characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 2004; 540 
53(7): 1721-1732.  541 
10. Wu XH, Liu CP, Xu KF, Mao XD, Zhu J, Jiang JJ et al. Reversal of hyperglycemia in diabetic rats by 542 
portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem 543 
cells. World J Gastroenterol 2007; 13(24): 3342-3349.  544 
11. Chakrabarti SK, Mirmira RG. Transcription factors direct the development and function of 545 
pancreatic beta cells. TRENDS in Endocrinology and Metabolism 2003; 14(2): 78-84.  546 
12. Gerace D, Martiniello-Wilks R, O'Brien BA, Simpson AM. The use of β-cell transcription factors in 547 
engineering artificial  β-cells from non-pancreatic tissue. Gene Ther 2015; 22(1): 1-8.  548 
13. Kojima H, Fujimiya M, Matsumura K, Younan P, Imaeda H, Maeda M et al. NeuroD-betacellulin 549 
gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 2003; 550 
9(5): 596-603.  551 
14. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of insulin-producing cells from human bone 552 
marrow mesenchymal stem cells by genetic manipulation. STEM CELLS 2007; 25(11): 2837-2844.  553 
28 
 
15. Li Y, Zhang R, Qiao H, Zhang H, Wang Y, Yuan H et al. Generation of insulin-producing cells from 554 
PDX-1 gene-modified human mesenchymal stem cells. Journal of Cellular Physiology 2007; 211(1): 555 
36-44.  556 
16. Lin G, Wang G, Liu G, Yang LJ, Chang LJ, Lue TF et al. Treatment of type 1 diabetes with adipose 557 
tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells Dev 2009; 558 
18(10): 1399-1406.  559 
17. Kajiyama H, Hamazaki TS, Tokuhara M, Masui S, Okabayashi K, Ohnuma K et al. Pdx1-transfected 560 
adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce 561 
hyperglycemia in diabetic mice. Int J Dev Biol 2010; 54(4): 699-705.  562 
18. Ren B, Tao C, Swan MA, Joachim N, Martiniello-Wilks R, Nassif NT et al. Pancreatic 563 
Transdifferentiation and Glucose-Regulated Production of Human Insulin in the H4IIE Rat Liver 564 
Cell Line. International Journal of Molecular Sciences 2016; 17(4): 534.  565 
19. Dodson BP, Levine AD. Challenges in the translation and commercialization of cell therapies. BMC 566 
Biotechnology 2015; 15(1): 70.  567 
20. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria 568 
for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy 569 
position statement. Cytotherapy 2006; 8(4): 315-317.  570 
21. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J et al. International Society for 571 
Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as 572 
potency release criterion for advanced phase clinical trials. Cytotherapy 2016; 18(2): 151-159.  573 
29 
 
22. Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I et al. Pancreatic and duodenal homeobox 574 
gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced 575 
hyperglycemia. Nat Med 2000; 6(5): 568-572.  576 
23. Council NHaMR. Australian code for the care and use of animals for scientific purposes, 2013. 577 
 578 
24. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ et al. Mesenchymal stem cells in the 579 
Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22(7): 1330-1337.  580 
25. Lawandi J, Tao C, Ren B, Williams P, Ling D, Swan MA et al. Reversal of diabetes following 581 
transplantation of an insulin-secreting human liver cell line: Melligen cells. Molecular Therapy — 582 
Methods & Clinical Development 2015; 2: 15011.  583 
26. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of 584 
mesenchymal stem cell in vitro. BMC Cell Biology 2006; 7(1): 14.  585 
27. Peffers MJ, Collins J, Fang Y, Goljanek-Whysall K, Rushton M, Loughlin J et al. Age-related changes 586 
in mesenchymal stem cells identified using a multi-omics approach. European cells & materials 587 
2016; 31: 136-159.  588 
28. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived 589 
mesenchymal stem cells: consequences for cell therapies. Mechanisms of ageing and 590 
development 2008; 129(3): 163-173.  591 
29. Nawrocka D, Kornicka K, Szydlarska J, Marycz K. Basic Fibroblast Growth Factor Inhibits Apoptosis 592 
and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients 593 
with Type 2 Diabetes by Reducing Cellular Oxidative Stress. Oxidative Medicine and Cellular 594 
Longevity 2017; 2017: 22.  595 
30 
 
30. Yu JM, Wu X, Gimble JM, Guan X, Freitas MA, Bunnell BA. Age-related changes in mesenchymal 596 
stem cells derived from rhesus macaque bone marrow. Aging cell 2011; 10(1): 66-79.  597 
31. Marędziak M, Marycz K, Tomaszewski KA, Kornicka K, Henry BM. The Influence of Aging on the 598 
Regenerative Potential of Human Adipose Derived Mesenchymal Stem Cells. Stem Cells 599 
International 2016; 2016: 2152435.  600 
32. Kretlow JD, Jin Y-Q, Liu W, Zhang WJ, Hong T-H, Zhou G et al. Donor age and cell passage affects 601 
differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biology 2008; 9(1): 602 
60. doi: 10.1186/1471-2121-9-60 603 
33. Kornicka K, Marycz K, Tomaszewski KA, Maredziak M, Smieszek A. The Effect of Age on Osteogenic 604 
and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) 605 
and the Impact of Stress Factors in the Course of the Differentiation Process. Oxidative Medicine 606 
and Cellular Longevity 2015; 2015: 20.  607 
34. Zhang D, Lu H, Chen Z, Wang Y, Lin J, Xu S et al. High glucose induces the aging of mesenchymal 608 
stem cells via Akt/mTOR signaling. Molecular medicine reports 2017; 16(2): 1685-1690.  609 
35. Bai ZM, Deng XD, Li JD, Li DH, Cao H, Liu ZX et al. Arterially transplanted mesenchymal stem cells 610 
in a mouse reversible unilateral ureteral obstruction model: in vivo bioluminescence imaging and 611 
effects on renal fibrosis. Chinese medical journal 2013; 126(10): 1890-1894.  612 
36. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. 613 
Nature biotechnology 2014; 32(3): 252-260.  614 
37. Podetz-Pedersen KM, Vezys V, Somia NV, Russell SJ, McIvor RS. Cellular immune response against 615 
firefly luciferase after sleeping beauty-mediated gene transfer in vivo. Human gene therapy 2014; 616 
25(11): 955-965.  617 
31 
 
38. Yin Y, Takahashi Y, Hamana A, Nishikawa M, Takakura Y. Effects of transgene expression level per 618 
cell in mice livers on induction of transgene-specific immune responses after hydrodynamic gene 619 
transfer. Gene Ther 2016; 23(7): 565-571.  620 
39. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility 621 
and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26(8): 622 
2173-2182.  623 
40. Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD et al. In vivo 624 
distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation 625 
models. Stem Cells 2007; 25(1): 220-227.  626 
41. Meyerrose TE, Roberts M, Ohlemiller KK, Vogler CA, Wirthlin L, Nolta JA et al. Lentiviral-627 
transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in 628 
a xenotransplantation model of human disease. Stem Cells 2008; 26(7): 1713-1722.  629 
42. Choi EW, Shin IS, Park SY, Yoon EJ, Kang SK, Ra JC et al. Characteristics of mouse adipose tissue-630 
derived stem cells and therapeutic comparisons between syngeneic and allogeneic adipose tissue-631 
derived stem cell transplantation in experimental autoimmune thyroiditis. Cell transplantation 632 
2014; 23(7): 873-887.  633 
43. Liang J, Li X, Zhang H, Wang D, Feng X, Wang H et al. Allogeneic mesenchymal stem cells 634 
transplantation in patients with refractory RA. Clinical rheumatology 2012; 31(1): 157-161.  635 
44. Qing-Song G, Ming-Yan Z, Lei W, Xiang-Jun F, Yu-Hua L, Zhi-Wei W et al. Combined Transfection 636 
of the Three Transcriptional Factors, PDX-1, NeuroD1, and MafA, Causes Differentiation of Bone 637 
Marrow Mesenchymal Stem Cells into Insulin-Producing Cells. Experimental Diabetes Research 638 
2012; 2012: 10.  639 
32 
 
45. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG et al. Production of pancreatic 640 
hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006; 641 
24(11): 1392-1401.  642 
46. Gerace D, Martiniello-Wilks R, Nassif NT, Lal S, Steptoe R, Simpson AM. CRISPR-targeted genome 643 
editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? 644 
Stem Cell Research & Therapy 2017; 8(1): 62.  645 
47. Frith JE, Thomson B, Genever PG. Dynamic three-dimensional culture methods enhance 646 
mesenchymal stem cell properties and increase therapeutic potential. Tissue engineering. Part C, 647 
Methods 2010; 16(4): 735-749.  648 
48. Karlsson C, Emanuelsson K, Wessberg F, Kajic K, Axell MZ, Eriksson PS et al. Human embryonic 649 
stem cell-derived mesenchymal progenitors—Potential in regenerative medicine. Stem Cell 650 
Research 2009; 3(1): 39-50.  651 
 652 
